
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is supported by dominant momentum in its incretin franchise, with Mounjaro sales up 65% to $10.72B and Zepbound up 49% to $5.35B in 3Q26, while the company also raised guidance by $5bn, signaling that demand is still underpenetrated and volume-led. Its growth case is strengthened by expanding access through the Medicare GLP-1 Bridge, rising international share, and a broadening portfolio that includes Foundayo, which generated $184M in 3Q26 and could become a meaningful new driver as diabetes and international launches progress. Beyond obesity, the pipeline adds further upside through oncology, immunology, and neuroscience, with retatrutide, Kisunla, and upcoming 2027 readouts offering multiple catalysts that could sustain revenue and EPS growth despite pricing pressure.
Bears say
Eli Lilly is vulnerable to a downside case in which obesity growth deteriorates faster than expected as pricing and competition intensify, pressuring operating margins, slowing EPS growth, and driving P/E compression to 21x. The company’s aggressive manufacturing expansion has helped, but supply constraints and allocation choices that favor higher-margin markets have intensified scrutiny over access, especially for lower-income patients and Medicare pricing. Key risks include weaker sales of Mounjaro, Zepbound, and Foundayo in US and international markets, underwhelming recent launches, possible quality or manufacturing issues, and disappointing capital deployment, even as Foundayo’s oral formulation could help by 2027-28.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Eli Lilly (LLY) Forecast
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares